Company Info






  Home > Archived Webinars >

Navigating FDA Oversight of Laboratory Developed Tests During an Era of Uncertainty



 
Our Price: $395.00

Product Code: WB-7185
Qty:

Product Info
 
About the Product
Includes 1 hour Windows Media Video File and PowerPoint presentations for immediate download.

Laboratory-developed tests (LDTs) continue to thrive and play a critical role in clinical decision making and patient management, particularly in the personalized medicine environment. The FDA has historically followed a process of “enforcement discretion” in refraining from regulating LDTs until factors such as a changing marketplace and changing technology caused FDA to seek greater oversight. Under the proposed framework released in 2014, the FDA would exercise greater oversight of labs developing LDTs. However, these labs would still be subject to oversight by the Centers for Medicare and Medicaid Services (CMS), which currently regulates laboratories under the Clinical Laboratory Improvement Amendments (CLIA) program.

  • Overview of key points in draft guidance and what industry needs to know
  • Practical tips to manage risk
  • Forecasting future regulatory developments


Speakers:

Elaine H. Tseng
Partner

King and Spalding

Lisa M. Dwyer
Partner
King and Spalding


Participants that will find this webinar most beneficial will be those involved in diagnostic companies. Job titles of attendees that will be most applicable for this session will be:

  • Regulatory Affairs
  • Legal Counsel


Share your knowledge of this product. Be the first to write a review »